Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Net Margin: 2012-2025

Historic Net Margin for Ptc Therapeutics (PTCT) over the last 14 years, with Sep 2025 value amounting to 7.53%.

  • Ptc Therapeutics' Net Margin rose 6173.00% to 7.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 42.25%, marking a year-over-year increase of 9202.00%. This contributed to the annual value of -45.03% for FY2024, which is 2178.00% up from last year.
  • Per Ptc Therapeutics' latest filing, its Net Margin stood at 7.53% for Q3 2025, which was up 120.78% from -36.25% recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Net Margin ranged from a high of 73.68% in Q1 2025 and a low of -109.07% during Q1 2021.
  • In the last 3 years, Ptc Therapeutics' Net Margin had a median value of -47.16% in 2024 and averaged -35.82%.
  • Over the last 5 years, Ptc Therapeutics' Net Margin had its largest YoY gain of 13,968bps in 2021, and its largest YoY loss of 3,745bps in 2021.
  • Over the past 5 years, Ptc Therapeutics' Net Margin (Quarterly) stood at -86.71% in 2021, then tumbled by 1,537bps to -102.08% in 2022, then skyrocketed by 5,134bps to -50.74% in 2023, then spiked by 1,983bps to -30.91% in 2024, then surged by 6,173bps to 7.53% in 2025.
  • Its last three reported values are 7.53% in Q3 2025, -36.25% for Q2 2025, and 73.68% during Q1 2025.